Top

Current Cardiovascular Imaging Reports

Published in:

01-09-2019 | Computed Tomography | Cardiac Computed Tomography (B Chow and G Small, Section Editors)

Computed Tomography in Heart Failure

Authors: Joshua G Kovoor, Aravinda Thiagalingam, Clara K Chow

Published in: Current Cardiovascular Imaging Reports | Issue 9/2019

Abstract

Purpose of Review

The purpose of this paper was to review the role of cardiac computed tomography (CCT) in both the diagnostic and management pathways of heart failure.

Recent Findings

CT has an essential role in non-invasively excluding coronary artery disease but also can provide additional information that can aid the investigation of the patient presenting with heart failure. CT images provide high-quality information about cardiac structure and pericardium. Cardiac anatomical information, such as the location and size of coronary sinuses, can assist in lead placement in cardiac resynchronisation therapy. Cardiac CT with fractional flow reserve calculation can also provide functional information on the severity of coronary stenosis. Cardiac CT with delayed contrast enhancement also has an emerging role in myocardial tissue characterisation which can contribute to risk stratification in cardiomyopathy patients. CT also may fit better into pathways of screening and monitoring of potential adverse cardiac events in the short-term and long-term assessment of cancer patients who may already be getting a CT for other reasons.

Summary

CT has an evolving role in both the diagnosis and management of heart failure and future research could examine the potential risks, benefits, efficiency and costs of clinical pathways where cardiac CT is more central to the diagnosis and management of patients with heart failure and possible cardiomyopathy.

Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11. https://doi.org/10.15420/cfr.2016:25:2.CrossRefPubMedPubMedCentral

Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25. https://doi.org/10.1002/ehf2.12005.CrossRefPubMed

Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19. https://doi.org/10.1161/HHF.0b013e318291329a.CrossRefPubMedPubMedCentral

Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev. 2013;9(2):123–7.CrossRefPubMedPubMedCentral

Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 2013;77(9):2209–17.CrossRefPubMed

Taylor AJ, Cerqueira M, Hodgson JM, Mark D, Min J, O’Gara P et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate use criteria for cardiac computed tomography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. J Cardiovasc Comput Tomogr. 2010;4(6):407 e1–33. doi:https://doi.org/10.1016/j.jcct.2010.11.001.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128.CrossRefPubMed

Ramos V, Bettencourt N, Silva J, Ferreira N, Chiribiri A, Schuster A, et al. Noninvasive anatomical and functional assessment of coronary artery disease. Rev Port Cardiol. 2015;34(4):223–32. https://doi.org/10.1016/j.repc.2014.10.008.CrossRefPubMed

Zhang LJ, Wang Y, Schoepf UJ, Meinel FG, Bayer RR 2nd, Qi L, et al. Image quality, radiation dose, and diagnostic accuracy of prospectively ECG-triggered high-pitch coronary CT angiography at 70 kVp in a clinical setting: comparison with invasive coronary angiography. Eur Radiol. 2016;26(3):797–806. https://doi.org/10.1007/s00330-015-3868-z.CrossRefPubMed

10.

Stehli J, Fuchs TA, Bull S, Clerc OF, Possner M, Buechel RR, et al. Accuracy of coronary CT angiography using a submillisievert fraction of radiation exposure: comparison with invasive coronary angiography. J Am Coll Cardiol. 2014;64(8):772–80. https://doi.org/10.1016/j.jacc.2014.04.079.CrossRefPubMed

11.

Uehara M, Takaoka H, Kobayashi Y, Funabashi N. Diagnostic accuracy of 320-slice computed-tomography for detection of significant coronary artery stenosis in patients with various heart rates and heart rhythms compared with conventional coronary-angiography. Int J Cardiol. 2013;167(3):809–15. https://doi.org/10.1016/j.ijcard.2012.02.017.CrossRefPubMed

12.

Petcherski O, Gaspar T, Halon DA, Peled N, Jaffe R, Molnar R, et al. Diagnostic accuracy of 256-row computed tomographic angiography for detection of obstructive coronary artery disease using invasive quantitative coronary angiography as reference standard. Am J Cardiol. 2013;111(4):510–5. https://doi.org/10.1016/j.amjcard.2012.10.036.CrossRefPubMed

13.

Madhok R, Aggarwal A. Comparison of 128-slice dual source CT coronary angiography with invasive coronary angiography. J Clin Diagn Res. 2014;8(6):RC08–11. https://doi.org/10.7860/JCDR/2014/9568.4514.CrossRefPubMedPubMedCentral

14.

Sajjadieh A, Hekmatnia A, Keivani M, Asoodeh A, Pourmoghaddas M, Sanei H. Diagnostic performance of 64-row coronary CT angiography in detecting significant stenosis as compared with conventional invasive coronary angiography. ARYA Atheroscler. 2013;9(2):157–63.PubMedPubMedCentral

15.

Hamilton-Craig C, Strugnell WE, Raffel OC, Porto I, Walters DL, Slaughter RE. CT angiography with cardiac MRI: non-invasive functional and anatomical assessment for the etiology in newly diagnosed heart failure. Int J Card Imaging. 2012;28(5):1111–22. https://doi.org/10.1007/s10554-011-9926-y.CrossRef

16.

Groothuis JG, Beek AM, Brinckman SL, Meijerink MR, van den Oever ML, Hofman MB, et al. Combined non-invasive functional and anatomical diagnostic work-up in clinical practice: the magnetic resonance and computed tomography in suspected coronary artery disease (MARCC) study. Eur Heart J. 2013;34(26):1990–8. https://doi.org/10.1093/eurheartj/eht077.CrossRefPubMed

17.

Li S, Tang X, Peng L, Luo Y, Dong R, Liu J. The diagnostic performance of CT-derived fractional flow reserve for evaluation of myocardial ischaemia confirmed by invasive fractional flow reserve: a meta-analysis. Clin Radiol. 2015;70(5):476–86. https://doi.org/10.1016/j.crad.2014.12.013.CrossRefPubMed

18.

Kim KP, Einstein AJ, Berrington de Gonzalez A. Coronary artery calcification screening: estimated radiation dose and cancer risk. Arch Intern Med. 2009;169(13):1188–94. https://doi.org/10.1001/archinternmed.2009.162.CrossRefPubMedPubMedCentral

19.

Alluri K, Joshi PH, Henry TS, Blumenthal RS, Nasir K, Blaha MJ. Scoring of coronary artery calcium scans: history, assumptions, current limitations, and future directions. Atherosclerosis. 2015;239(1):109–17. https://doi.org/10.1016/j.atherosclerosis.2014.12.040.CrossRefPubMed

20.

Bakhshi H, Ambale-Venkatesh B, Yang X, Ostovaneh MR, Wu CO, Budoff M, et al. Progression of coronary artery calcium and incident heart failure: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2017;6(4). https://doi.org/10.1161/JAHA.116.005253.

21.

Ito T, Suzuki Y, Ehara M, Matsuo H, Teramoto T, Terashima M, et al. Impact of epicardial fat volume on coronary artery disease in symptomatic patients with a zero calcium score. Int J Cardiol. 2013;167(6):2852–8. https://doi.org/10.1016/j.ijcard.2012.07.026.CrossRefPubMed

22.

Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–45. https://doi.org/10.1056/NEJMoa072100.CrossRefPubMed

23.

Sarwar A, Shaw LJ, Shapiro MD, Blankstein R, Hoffmann U, Cury RC, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging. 2009;2(6):675–88. https://doi.org/10.1016/j.jcmg.2008.12.031.CrossRefPubMed

24.

Nasir K, Clouse M. Role of nonenhanced multidetector CT coronary artery calcium testing in asymptomatic and symptomatic individuals. Radiology. 2012;264(3):637–49. https://doi.org/10.1148/radiol.12110810.CrossRefPubMed

25.

ten Kate GJ, Caliskan K, Dedic A, Meijboom WB, Neefjes LA, Manintveld OC, et al. Computed tomography coronary imaging as a gatekeeper for invasive coronary angiography in patients with newly diagnosed heart failure of unknown aetiology. Eur J Heart Fail. 2013;15(9):1028–34. https://doi.org/10.1093/eurjhf/hft090.CrossRefPubMed

26.

Mylonas I, Alam M, Amily N, Small G, Chen L, Yam Y, et al. Quantifying coronary artery calcification from a contrast-enhanced cardiac computed tomography angiography study. Eur Heart J Cardiovasc Imaging. 2014;15(2):210–5. https://doi.org/10.1093/ehjci/jet144.CrossRefPubMed

27.

Whitlock MC, Yeboah J, Burke GL, Chen H, Klepin HD, Hundley WG. Cancer and its association with the development of coronary artery calcification: an assessment from the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2015;4(11). https://doi.org/10.1161/JAHA.115.002533.

28.

Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67. https://doi.org/10.1056/NEJMra1100265.CrossRefPubMed

29.

Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263–302. https://doi.org/10.2165/00002018-200022040-00002.CrossRefPubMed

30.

Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–7.CrossRef

31.

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79. https://doi.org/10.1002/cncr.11407.CrossRefPubMed

32.

Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758–63.CrossRefPubMed

33.

Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302–13. https://doi.org/10.1056/NEJMoa043681.CrossRefPubMed

34.

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47. https://doi.org/10.1016/j.jacc.2009.02.050.CrossRefPubMed

35.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98. https://doi.org/10.1056/NEJMoa043445.CrossRefPubMed

36.

Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9. https://doi.org/10.1016/S0140-6736(07)61865-0.CrossRefPubMedPubMedCentral

37.

Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21. https://doi.org/10.1200/JCO.2002.20.5.1215.CrossRefPubMed

38.

Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–86. https://doi.org/10.4065/83.6.679.CrossRefPubMed

39.

Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500–8. https://doi.org/10.1002/cncr.23460.CrossRefPubMed

40.

Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med. 2013;23(4):104–13. https://doi.org/10.1016/j.tcm.2012.09.008.CrossRefPubMedPubMedCentral

41.

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. https://doi.org/10.1016/j.jacc.2009.03.095.CrossRefPubMed

42.

Arsanjani R, Berman DS, Gransar H, Cheng VY, Dunning A, Lin FY, et al. Left ventricular function and volume with coronary CT angiography improves risk stratification and identification of patients at risk for incident mortality: results from 7758 patients in the prospective multinational CONFIRM observational cohort study. Radiology. 2014;273(1):70–7. https://doi.org/10.1148/radiol.14122816.CrossRefPubMed

43.

Rigolli M, Anandabaskaran S, Christiansen JP, Whalley GA. Bias associated with left ventricular quantification by multimodality imaging: a systematic review and meta-analysis. Open Heart. 2016;3(1):e000388. https://doi.org/10.1136/openhrt-2015-000388.CrossRefPubMedPubMedCentral

44.

Schlosser T, Mohrs OK, Magedanz A, Voigtlander T, Schmermund A, Barkhausen J. Assessment of left ventricular function and mass in patients undergoing computed tomography (CT) coronary angiography using 64-detector-row CT: comparison to magnetic resonance imaging. Acta Radiol. 2007;48(1):30–5. https://doi.org/10.1080/02841850601067611.CrossRefPubMed

45.

Nasir K, Katz R, Mao S, Takasu J, Bomma C, Lima JA, et al. Comparison of left ventricular size by computed tomography with magnetic resonance imaging measures of left ventricle mass and volumes: the multi-ethnic study of atherosclerosis. J Cardiovasc Comput Tomogr. 2008;2(3):141–8. https://doi.org/10.1016/j.jcct.2008.01.003.CrossRefPubMed

46.

Boogers MJ, van Werkhoven JM, Schuijf JD, Delgado V, El-Naggar HM, Boersma E, et al. Feasibility of diastolic function assessment with cardiac CT: feasibility study in comparison with tissue Doppler imaging. JACC Cardiovasc Imaging. 2011;4(3):246–56. https://doi.org/10.1016/j.jcmg.2010.11.017.CrossRefPubMed

47.

Flachskampf FA, Biering-Sorensen T, Solomon SD, Duvernoy O, Bjerner T, Smiseth OA. Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging. 2015;8(9):1071–93. https://doi.org/10.1016/j.jcmg.2015.07.004.CrossRefPubMed

48.

Shen Z, Lee O, Taguchi K. Beam hardening and motion artifacts in cardiac CT: evaluation and iterative correction method. SPIE Medical Imaging SPIE. 2016.

49.

Rodriguez-Granillo GA. Delayed enhancement cardiac computed tomography for the assessment of myocardial infarction: from bench to bedside. Cardiovasc Diagn Ther. 2017;7(2):159–70. https://doi.org/10.21037/cdt.2017.03.16.CrossRefPubMedPubMedCentral

50.

Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging. 2016;9(12):1392–402. https://doi.org/10.1016/j.jcmg.2016.02.031.CrossRefPubMed

51.

Ganesan AN, Gunton J, Nucifora G, McGavigan AD, Selvanayagam JB. Impact of late gadolinium enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol. 2018;254:230–7. https://doi.org/10.1016/j.ijcard.2017.10.094.CrossRefPubMed

52.

Zaman S, Goldberger JJ, Kovoor P. Sudden death risk-stratification in 2018-2019: the old and the new. Heart Lung Circ. 2019;28(1):57–64. https://doi.org/10.1016/j.hlc.2018.08.027.CrossRefPubMed

53.

Lardo AC, Cordeiro MA, Silva C, Amado LC, George RT, Saliaris AP, et al. Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scar. Circulation. 2006;113(3):394–404. https://doi.org/10.1161/CIRCULATIONAHA.105.521450.CrossRefPubMedPubMedCentral

54.

Schuleri KH, Centola M, George RT, Amado LC, Evers KS, Kitagawa K, et al. Characterization of peri-infarct zone heterogeneity by contrast-enhanced multidetector computed tomography: a comparison with magnetic resonance imaging. J Am Coll Cardiol. 2009;53(18):1699–707. https://doi.org/10.1016/j.jacc.2009.01.056.CrossRefPubMedPubMedCentral

55.

Shiozaki AA, Senra T, Arteaga E, Martinelli Filho M, Pita CG, Avila LF, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr. 2013;7(3):173–81. https://doi.org/10.1016/j.jcct.2013.04.002.CrossRefPubMedPubMedCentral

56.

Bogaert J, Francone M. Pericardial disease: value of CT and MR imaging. Radiology. 2013;267(2):340–56. https://doi.org/10.1148/radiol.13121059.CrossRefPubMed

57.

Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ, et al. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging. 2015;16(1):12–31. https://doi.org/10.1093/ehjci/jeu128.CrossRefPubMed

58.

Al-Mallah MH, Almasoudi F, Ebid M, Ahmed AM, Jamiel A. Multimodality imaging of pericardial diseases. Curr Treat Options Cardiovasc Med. 2017;19(12):89. https://doi.org/10.1007/s11936-017-0590-y.CrossRefPubMed

59.

Wang ZJ, Reddy GP, Gotway MB, Yeh BM, Hetts SW, Higgins CB. CT and MR imaging of pericardial disease. Radiographics. 2003;23 Spec No::S167–80. https://doi.org/10.1148/rg.23si035504.CrossRefPubMed

60.

Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases. Rev Esp Cardiol (Engl Ed). 2015;68(12):1126. https://doi.org/10.1016/j.rec.2015.10.008.CrossRef

61.

Ardhanari S, Yarlagadda B, Parikh V, Dellsperger KC, Chockalingam A, Balla S, et al. Systematic review of non-invasive cardiovascular imaging in the diagnosis of constrictive pericarditis. Indian Heart J. 2017;69(1):57–67. https://doi.org/10.1016/j.ihj.2016.06.004.CrossRefPubMed

62.

Alter P, Figiel JH, Rupp TP, Bachmann GF, Maisch B, Rominger MB. MR, CT, and PET imaging in pericardial disease. Heart Fail Rev. 2013;18(3):289–306. https://doi.org/10.1007/s10741-012-9309-z.CrossRefPubMed

63.

Imazio M, Brucato A, Derosa FG, Lestuzzi C, Bombana E, Scipione F, et al. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med (Hagerstown). 2009;10(3):217–30. https://doi.org/10.2459/JCM.0b013e328322f9b1.CrossRef

64.

Smolis-Bak E, Dabrowski R, Piotrowicz E, Chwyczko T, Dobraszkiewicz-Wasilewska B, Kowalik I, et al. Hospital-based and telemonitoring guided home-based training programs: effects on exercise tolerance and quality of life in patients with heart failure (NYHA class III) and cardiac resynchronization therapy. A randomized, prospective observation. Int J Cardiol. 2015;199:442–7. https://doi.org/10.1016/j.ijcard.2015.07.041.CrossRefPubMed

65.

Kyriacou A, Pabari PA, Mayet J, Peters NS, Davies DW, Lim PB, et al. Cardiac resynchronization therapy and AV optimization increase myocardial oxygen consumption, but increase cardiac function more than proportionally. Int J Cardiol. 2014;171(2):144–52. https://doi.org/10.1016/j.ijcard.2013.10.026.CrossRefPubMedPubMedCentral

66.

Frigerio M, Lunati M, Pasqualucci D, Vargiu S, Foti G, Pedretti S, et al. Left ventricular ejection fraction overcrossing 35% after one year of cardiac resynchronization therapy predicts long term survival and freedom from sudden cardiac death: single center observational experience. Int J Cardiol. 2014;172(1):64–71. https://doi.org/10.1016/j.ijcard.2013.12.005.CrossRefPubMed

67.

Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation. 2003;108(21):2596–603. https://doi.org/10.1161/01.CIR.0000096580.26969.9A.CrossRefPubMed

68.

Puglisi A, Lunati M, Marullo AG, Bianchi S, Feccia M, Sgreccia F, et al. Limited thoracotomy as a second choice alternative to transvenous implant for cardiac resynchronisation therapy delivery. Eur Heart J. 2004;25(12):1063–9. https://doi.org/10.1016/j.ehj.2004.04.016.CrossRefPubMed

69.

Ma H, Wang X, Xie H, Sun C, Wen Z, Liu Y, et al. Characterization of the cardiac venous system in heart failure patients using 256-slice CT. Int J Cardiol. 2016;203:447–8. https://doi.org/10.1016/j.ijcard.2015.10.135.CrossRefPubMed

70.

Sommer A, Kronborg MB, Norgaard BL, Poulsen SH, Bouchelouche K, Bottcher M, et al. Multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. Eur J Heart Fail. 2016;18(11):1365–74. https://doi.org/10.1002/ejhf.530.CrossRefPubMed

71.

Alhailiy AB, Ekpo EU, Kench PL, Ryan EA, Brennan PC, McEntee M. The associated factors for radiation dose variation in cardiac CT angiography. Br J Radiol. 2019;92(1096):20180793. https://doi.org/10.1259/bjr.20180793.CrossRefPubMedPubMedCentral

72.

Blomster JI, O'Rourke J, Choudhary P, Thiagalingam A, Kovoor P, Adler J, et al. Patient selection essential for computed tomography coronary angiography. Scand Cardiovasc J. 2016;50(4):206–12. https://doi.org/10.1080/14017431.2016.1177659.CrossRefPubMed

73.

Vorre MM, Abdulla J. Diagnostic accuracy and radiation dose of CT coronary angiography in atrial fibrillation: systematic review and meta-analysis. Radiology. 2013;267(2):376–86. https://doi.org/10.1148/radiol.13121224.CrossRefPubMed

74.

Kosmala A, Petritsch B, Weng AM, Bley TA, Gassenmaier T. Radiation dose of coronary CT angiography with a third-generation dual-source CT in a “real-world” patient population. Eur Radiol. 2018;29:4341–8. https://doi.org/10.1007/s00330-018-5856-6.CrossRefPubMed

75.

Stocker TJ, Deseive S, Leipsic J, Hadamitzky M, Chen MY, Rubinshtein R, et al. Reduction in radiation exposure in cardiovascular computed tomography imaging: results from the PROspective multicenter registry on radiaTion dose Estimates of cardiac CT angIOgraphy iN daily practice in 2017 (PROTECTION VI). Eur Heart J. 2018;39(41):3715–23. https://doi.org/10.1093/eurheartj/ehy546.CrossRefPubMedPubMedCentral

76.

Menke J, Unterberg-Buchwald C, Staab W, Sohns JM, Seif Amir Hosseini A, Schwarz A. Head-to-head comparison of prospectively triggered vs retrospectively gated coronary computed tomography angiography: meta-analysis of diagnostic accuracy, image quality, and radiation dose. Am Heart J. 2013;165(2):154–63 e3. https://doi.org/10.1016/j.ahj.2012.10.026.CrossRefPubMed

77.

Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology. 2013;268(3):719–28. https://doi.org/10.1148/radiol.13122276.CrossRefPubMed

78.

Lee J, Cho JY, Lee HJ, Jeong YY, Kim CK, Park BK, et al. Contrast-induced nephropathy in patients undergoing intravenous contrast-enhanced computed tomography in Korea: a multi-institutional study in 101487 patients. Korean J Radiol. 2014;15(4):456–63. https://doi.org/10.3348/kjr.2014.15.4.456.CrossRefPubMedPubMedCentral

79.

Jung JW, Choi YH, Park CM, Park HW, Cho SH, Kang HR. Outcomes of corticosteroid prophylaxis for hypersensitivity reactions to low osmolar contrast media in high-risk patients. Ann Allergy Asthma Immunol. 2016;117(3):304–9 e1. https://doi.org/10.1016/j.anai.2016.07.010.CrossRefPubMed

80.

Darlington M, Gueret P, Laissy JP, Pierucci AF, Maoulida H, Quelen C, et al. Cost-effectiveness of computed tomography coronary angiography versus conventional invasive coronary angiography. Eur J Health Econ. 2015;16(6):647–55. https://doi.org/10.1007/s10198-014-0616-2.CrossRefPubMed

81.

Igarashi A, Fujito K, Hirano M, Fukuda T. Cost minimization analysis of beta-blocker at the time of CT imaging for suspected of coronary heart disease in Japan. J Med Econ. 2014;17(2):142–7. https://doi.org/10.3111/13696998.2013.877021.CrossRefPubMed

Title: Computed Tomography in Heart Failure
Authors: Joshua G Kovoor
Aravinda Thiagalingam
Clara K Chow
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Computed Tomography
Cardiomyopathy
Computed Tomography
Heart Failure
Arterial Diseases
Published in: Current Cardiovascular Imaging Reports / Issue 9/2019
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI: https://doi.org/10.1007/s12410-019-9512-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Computed Tomography in Heart Failure

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page